Clesrovimab Biosimilar - Research Grade

Human

RSV

>1mg/ml

IgG1 - kappa

CHO Cells

Motavizumab Biosimilar - Research Grade (ICH5169), Felvizumab Biosimilar - Research Grade (ICH5546), Gontivimab Biosimilar - Research Grade (ICH5580), Nirsevimab Biosimilar - Research Grade (ICH5712), Suptavumab Biosimilar - Research Grade (ICH5887)

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

This product is a research-grade biosimilar of clesrovimab, supplied as an unconjugated, non-therapeutic analog of the originator antibody for research use only. It is built to reproduce the antigen-binding specificity of clesrovimab, a half-life-extended human IgG1 (kappa) monoclonal antibody directed against the respiratory syncytial virus (RSV) fusion (F) glycoprotein. The originator was developed for the prevention of RSV-associated lower respiratory tract disease in infants and reached approval in 2025 (marketed as Enflonsia). This biosimilar is not a clinical drug and is not intended for diagnostic or therapeutic use; it is intended as a reference tool for in-vitro and functional work such as binding characterization, neutralization assays, epitope and competition studies, and as a benchmarking or control reagent in RSV antibody research. It is offered as a research antibody standard, with low-endotoxin material suitable for cell-based and functional assays. Because clesrovimab targets a viral (non-host) antigen and the originator is a human antibody, standard rodent in-vivo dosing paradigms generally do not apply. Investigators should confirm target identity, lot-specific characteristics, and suitability for their particular application prior to use. Respiratory syncytial virus (RSV) is an enveloped negative-sense RNA virus and a leading cause of lower respiratory tract infection in infants, older adults, and immunocompromised individuals. The RSV fusion (F) glycoprotein mediates fusion of the viral envelope with the host cell membrane and is the principal target of neutralizing antibodies. F protein transitions from a metastable prefusion conformation to a stable postfusion form; several antigenic sites (including sites Ø, II, and IV) are recognized by protective antibodies. Clesrovimab binds antigenic site IV, an epitope presented on both the prefusion and postfusion conformations of F, distinguishing it from prefusion-only binders such as those targeting site Ø. Site IV is highly conserved across RSV-A and RSV-B subgroups, a feature associated with broad strain coverage and a reduced likelihood of escape mutations. Antibody binding at this site blocks membrane fusion and viral entry, neutralizing infectivity.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Clesrovimab biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Clesrovimab biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Clesrovimab biosimilar target?

A: It is a non-therapeutic research analog of Clesrovimab that recognizes and neutralizes RSV; for research use only.